Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Wagner, Sandro M., Melchardt, Thomas, Egle, Alexander, Magnes, Teresa, Skrabs, Cathrin, Staber, Philipp, Simonitsch‐Klupp, Ingrid, Panny, Michael, Lehner, Barbara, Greil, Richard, Keil, Felix, Jäger, Ulrich, Sillaber, Christian
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065019/
https://ncbi.nlm.nih.gov/pubmed/31838747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13368
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados